Empagliflozin lowers death risk in HF in non Diabetics also: NEJM
USA: The use of SGLT2 inhibitor empagliflozin in heart failure patients lowers the risk of cardiovascular death and hospitalization for heart failure regardless of the absence or presence of diabetes, suggests a recent study in NEJM.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are known to reduce the risk of hospitalization in heart failure patients regardless of the absence or presence of diabetes. More evidence is required on the effects of these drugs across the broad spectrum of heart failure, including those having a markedly reduced ejection fraction. To determine the same, Milton Packer, Baylor University Medical Center, Dallas, and colleagues conducted a double-blind trial that included 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less. They were randomly assigned to receive 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.